|
liver cancer |
22 |
|
hcc |
19 |
|
animals |
18 |
|
humans |
17 |
|
metastasis |
17 |
|
cell line, tumor |
15 |
|
mice |
15 |
|
tumor-initiating cells |
15 |
|
cancer stem cells |
14 |
|
hepatocellular carcinoma |
14 |
|
male |
14 |
|
mice, nude |
14 |
|
proteomics |
14 |
|
arginine methylation |
13 |
|
cancer stemness |
13 |
|
cd133 |
12 |
|
gene expression |
12 |
|
tumor microenvironment |
11 |
|
antigens, cd - genetics - metabolism |
10 |
|
antigens, cd - metabolism |
10 |
|
arhgap fusions |
10 |
|
biobank |
10 |
|
cell proliferation |
10 |
|
chemoresistance |
10 |
|
drug screening |
10 |
|
ebv genome |
10 |
|
gastric cancer |
10 |
|
glycoproteins - metabolism |
10 |
|
heterogeneity |
10 |
|
intercellular communication |
10 |
|
liver regeneration |
10 |
|
neutralizing antibody |
10 |
|
organoid culture |
10 |
|
peptides - metabolism |
10 |
|
rhoa mutations |
10 |
|
sorafenib |
10 |
|
transcriptome sequencing |
10 |
|
whole-exome sequencing |
10 |
|
blotting, western |
9 |
|
epigenetics |
9 |
|
escc |
9 |
|
gene expression regulation, neoplastic |
9 |
|
mice, scid |
9 |
|
prostate cancer |
9 |
|
signal transduction |
9 |
|
transplantation, heterologous |
9 |
|
carcinoma, hepatocellular - genetics - metabolism |
8 |
|
carrier proteins - metabolism |
8 |
|
cell differentiation |
8 |
|
chemokine cxcl1 - physiology |
8 |
|
etv4 |
8 |
|
glycoproteins - deficiency - genetics - metabolism |
8 |
|
glycoproteins - genetics - metabolism |
8 |
|
interleukin-8 - deficiency - genetics - physiology |
8 |
|
liver - metabolism - pathology - physiopathology |
8 |
|
liver neoplasms - genetics - metabolism |
8 |
|
liver neoplasms - metabolism - pathology |
8 |
|
medical sciences |
8 |
|
neoplasm transplantation |
8 |
|
nrp2 |
8 |
|
oncology |
8 |
|
prostatic neoplasms - pathology |
8 |
|
rna‐seq |
8 |
|
xenograft model antitumor assays |
8 |
|
aged |
7 |
|
aged, 80 and over |
7 |
|
cancer metabolism |
7 |
|
cell cycle |
7 |
|
circulating mirna |
7 |
|
e-cadherin |
7 |
|
epigenetic regulation |
7 |
|
esophageal cancer |
7 |
|
id‐1 |
7 |
|
middle aged |
7 |
|
mir‐338‐5p |
7 |
|
reverse transcriptase polymerase chain reaction |
7 |
|
sorafenib resistance |
7 |
|
adult |
6 |
|
antigens, differentiation - metabolism |
6 |
|
carcinogenicity tests |
6 |
|
carcinoma, hepatocellular - metabolism - pathology |
6 |
|
cell division |
6 |
|
cell separation |
6 |
|
female |
6 |
|
glycolysis |
6 |
|
hepatocellular carcinomas |
6 |
|
histone modifications |
6 |
|
matrix stiffness |
6 |
|
mechanoepigenetics |
6 |
|
muscle development |
6 |
|
neovascularization, pathologic |
6 |
|
phenotype |
6 |
|
pkm2 |
6 |
|
prmt6 |
6 |
|
prognosis |
6 |
|
stem cells - metabolism - pathology |
6 |
|
thbs2 |
6 |
|
tumor markers, biological - metabolism |
6 |
|
warburg effect |
6 |
|
aggressiveness |
5 |
|
aldehyde dehydrogenase - metabolism |
5 |
|
antibody therapy |
5 |
|
antigens, cd - biosynthesis - physiology |
5 |
|
antineoplastic agents - pharmacology |
5 |
|
anxa3 |
5 |
|
carcinoma, hepatocellular - metabolism |
5 |
|
carcinoma, squamous cell - genetics - pathology |
5 |
|
carrier proteins - genetics |
5 |
|
cell survival - drug effects - physiology |
5 |
|
chemoprevention - methods |
5 |
|
chromans - pharmacology |
5 |
|
drug delivery systems - methods |
5 |
|
drug resistance, neoplasm |
5 |
|
drug resistance, neoplasm - physiology |
5 |
|
fascin |
5 |
|
glycoproteins - biosynthesis - physiology |
5 |
|
immunohistochemistry |
5 |
|
liver neoplasms - drug therapy - enzymology |
5 |
|
map kinase signaling system - drug effects - physiology |
5 |
|
microfilament proteins - genetics |
5 |
|
mouth neoplasms - genetics - pathology |
5 |
|
neoplasm invasiveness |
5 |
|
neoplasm staging |
5 |
|
neoplastic stem cells - drug effects |
5 |
|
neoplastic stem cells - drug effects - metabolism |
5 |
|
neoplastic stem cells - drug effects - metabolism - pathology |
5 |
|
neoplastic stem cells - drug effects - pathology |
5 |
|
oscc |
5 |
|
peptides - physiology |
5 |
|
prostatic neoplasms - drug therapy - pathology - prevention and control |
5 |
|
proteoglycans - pharmacology - therapeutic use |
5 |
|
proto-oncogene proteins c-akt - biosynthesis - physiology |
5 |
|
regorafenib |
5 |
|
self-renewal |
5 |
|
signal transduction - drug effects - physiology |
5 |
|
smoking |
5 |
|
stem cell |
5 |
|
survival |
5 |
|
tocotrienol |
5 |
|
tumor cells, cultured |
5 |
|
vitamin e |
5 |
|
vitamin e - analogs & derivatives - pharmacology |
5 |
|
adaptor proteins, signal transducing |
4 |
|
adaptor proteins, signal transducing - metabolism |
4 |
|
adenocarcinoma - pathology |
4 |
|
antineoplastic combined chemotherapy protocols - pharmacology |
4 |
|
blotting, western - methods |
4 |
|
brain ischemia - physiopathology |
4 |
|
cancer-associated fibroblasts (cafs) |
4 |
|
carboxypeptidase h - chemistry - genetics |
4 |
|
carcinoma, hepatocellular - enzymology - pathology |
4 |
|
carcinoma, hepatocellular - genetics - metabolism - secondary |
4 |
|
carcinoma, squamous cell - drug therapy - genetics - metabolism - pathology |
4 |
|
caveolin 1 - metabolism |
4 |
|
caveolin-1 |
4 |
|
cell death - drug effects |
4 |
|
cell growth processes - drug effects |
4 |
|
cell movement - drug effects |
4 |
|
chi-square distribution |
4 |
|
cisplatin - administration & dosage - pharmacology |
4 |
|
dna-binding proteins - genetics |
4 |
|
down-regulation - drug effects |
4 |
|
drug synergism |
4 |
|
electrophoresis, gel, two-dimensional |
4 |
|
enzyme inhibitors - pharmacology |
4 |
|
epithelial cells - drug effects - pathology |
4 |
|
er stress |
4 |
|
flow cytometry |
4 |
|
fra1 |
4 |
|
gene expression profiling |
4 |
|
gene expression regulation - drug effects |
4 |
|
glutamine metabolism |
4 |
|
hbx |
4 |
|
head and neck neoplasms - drug therapy - genetics - metabolism - pathology |
4 |
|
hepatocyte growth factor (hgf) |
4 |
|
hey1 |
4 |
|
hpd |
4 |
|
hypoxia |
4 |
|
i-kappa b kinase - genetics - metabolism |
4 |
|
immunohistochemistry - methods |
4 |
|
ischemic stroke |
4 |
|
isoenzymes - metabolism |
4 |
|
lim domain proteins |
4 |
|
liver cancer stem cells |
4 |
|
liver neoplasms - enzymology - pathology |
4 |
|
liver neoplasms - genetics - metabolism - pathology |
4 |
|
lmo2 |
4 |
|
lymphatic metastasis |
4 |
|
mesoderm - drug effects - pathology |
4 |
|
metalloproteins - genetics |
4 |
|
microfilament proteins - genetics - metabolism |
4 |
|
mim-b |
4 |
|
mir-142-3p |
4 |
|
mtor signaling |
4 |
|
neoplasm proteins - genetics - metabolism |
4 |
|
neoplasm proteins - metabolism |
4 |
|
neoplastic stem cells - enzymology - pathology |
4 |
|
nf-kappa b - antagonists & inhibitors - biosynthesis - genetics - metabolism |
4 |
|
ng-nitroarginine methyl ester - pharmacology |
4 |
|
nitric oxide |
4 |
|
nitric oxide - physiology |
4 |
|
nitric oxide donors - pharmacology |
4 |
|
nitric oxide synthase |
4 |
|
nitric oxide synthase - antagonists & inhibitors |
4 |
|
nutrient deprivation |
4 |
|
oligonucleotide array sequence analysis |
4 |
|
ornithine - analogs & derivatives - pharmacology |
4 |
|
pentacyclic triterpenes |
4 |
|
polymerase chain reaction |
4 |
|
protein arginine methyltransferase 6 |
4 |
|
protein isoforms |
4 |
|
protein structure, tertiary |
4 |
|
proto-oncogene proteins |
4 |
|
rats |
4 |
|
rats, sprague-dawley |
4 |
|
real-time quantitative pc |
4 |
|
reperfusion injury - physiopathology |
4 |
|
rna, messenger - analysis |
4 |
|
rna, messenger - metabolism |
4 |
|
rna, neoplasm - analysis |
4 |
|
rna-seq |
4 |
|
scd1 |
4 |
|
t-ics |
4 |
|
transfection |
4 |
|
triterpenes - administration & dosage - pharmacology |
4 |
|
tumor-initiating cells (t-ics) |
4 |
|
tyrosine catabolism |
4 |
|
aldh |
3 |
|
antigens, cd |
3 |
|
antineoplastic agents - therapeutic use |
3 |
|
bile duct neoplasms - genetics - pathology |
3 |
|
bile ducts, intrahepatic - pathology |
3 |
|
bleeding |
3 |
|
bone marrow cells |
3 |
|
carcinoma, hepatocellular - blood supply - metabolism - pathology - therapy |
3 |
|
carcinoma, hepatocellular - drug therapy |
3 |
|
carcinoma, hepatocellular - drug therapy - metabolism - pathology |
3 |
|
cd24 antigen |
3 |
|
cd68 |
3 |
|
cell division - drug effects |
3 |
|
cell line |
3 |
|
cell renewal |
3 |
|
chemotherapy drug resistance |
3 |
|
cholangiocarcinoma |
3 |
|
cholangiocarcinoma - genetics - pathology |
3 |
|
chromosome aberrations |
3 |
|
chromosome banding |
3 |
|
cisplatin |
3 |
|
cscs |
3 |
|
drug design |
3 |
|
glycoproteins |
3 |
|
hepatocytes |
3 |
|
hepatocytes - drug effects - metabolism - pathology |
3 |
|
hkgz-cc |
3 |
|
il-13 |
3 |
|
in situ hybridization, fluorescence - methods |
3 |
|
ipscs |
3 |
|
karyotyping |
3 |
|
liver - drug effects - metabolism - pathology |
3 |
|
liver neoplasms - blood supply - metabolism - pathology - therapy |
3 |
|
liver neoplasms - drug therapy |
3 |
|
liver neoplasms - drug therapy - metabolism - pathology |
3 |
|
liver regeneration - physiology |
3 |
|
liver transplantation |
3 |
|
macrophage |
3 |
|
micrornas - metabolism |
3 |
|
mirna |
3 |
|
models, biological |
3 |
|
neoplastic stem cells - metabolism - pathology |
3 |
|
neovascularization, pathologic - pathology |
3 |
|
oval cells |
3 |
|
pentacyclic triterpenes - therapeutic use |
3 |
|
peptides |
3 |
|
platelet apheresis |
3 |
|
portal vein thrombosis |
3 |
|
pten phosphohydrolase - physiology |
3 |
|
rtk |
3 |
|
shp2 |
3 |
|
stat3 protein |
3 |
|
stem cells - cytology - metabolism |
3 |
|
stem cells - drug effects - metabolism - pathology |
3 |
|
thrombocytosis |
3 |
|
tumor progression |
3 |
|
adipocytes |
2 |
|
alk |
2 |
|
autophagy |
2 |
|
cancer |
2 |
|
carcinoma, hepatocellular - etiology - pathology |
2 |
|
carcinoma, hepatocellular - physiopathology |
2 |
|
carrier proteins - genetics - physiology |
2 |
|
cenpf |
2 |
|
cervical canceri |
2 |
|
cholecystokinin |
2 |
|
chromosome 12p12.1 |
2 |
|
csc |
2 |
|
dna helicases - physiology |
2 |
|
dna-binding proteins - physiology |
2 |
|
drug resistance |
2 |
|
embryonic stem cell |
2 |
|
epithelial-mesenchymal transition - physiology |
2 |
|
ferritin |
2 |
|
ferroptosis |
2 |
|
g2/m transition |
2 |
|
gf-1r |
2 |
|
glycogen synthase kinase 3 - physiology |
2 |
|
glycoproteins - genetics |
2 |
|
hepatocyte differentiation |
2 |
|
ifn-γ |
2 |
|
immune |
2 |
|
lcm |
2 |
|
liver development |
2 |
|
liver neoplasms - etiology - pathology |
2 |
|
liver neoplasms - physiopathology |
2 |
|
metabolic rewiring |
2 |
|
metabolism |
2 |
|
micrornas - genetics - metabolism |
2 |
|
neoplastic stem cells - metabolism |
2 |
|
oncofetal properties |
2 |
|
oncogenic driver |
2 |
|
oxphos |
2 |
|
parp inhibitors |
2 |
|
pluripotent transcriptome |
2 |
|
prognosis factor |
2 |
|
prostate tumor-initiating cells |
2 |
|
protein stability |
2 |
|
rock2 |
2 |
|
scyl3 |
2 |
|
signal transduction - genetics |
2 |
|
smal-pcr dna fingerprinting |
2 |
|
sonic hedgehog |
2 |
|
sox5 |
2 |
|
tie-2 |
2 |
|
trop-2 |
2 |
|
tumor initiating cells |
2 |
|
tumor suppressor |
2 |
|
urb1-as1 |
2 |
|
cancer cell plasticity |
1 |
|
cancer-initiating cells |
1 |
|
clinicopathology |
1 |
|
epstein-barr virus |
1 |
|
genomic landscape |
1 |
|
hepatocyte organoid |
1 |
|
hepatocyte proliferation |
1 |
|
human liver organoid |
1 |
|
immunosuppression |
1 |
|
intrahepatic cholangiocarcinoma |
1 |
|
microenvironment |
1 |
|
microrna |
1 |
|
plasticity |
1 |
|
recurrence |
1 |
|
signaling |
1 |
|
therapeutic targeting |
1 |
|
tumor immune microenvironment |
1 |
|
tumor recurrence |
1 |
